ClinicalTrials.gg
Not yet recruitingNCT07691489Updated Oct 1, 2026

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

A Phase 2 interventional study of Fam-Trastuzumab Deruxtecan-Nxki in Colorectal Cancer, Adenocarcinoma of the Colon and Adenocarcinoma of the Rectum, sponsored by Memorial Sloan Kettering Cancer Center. Not yet recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 1, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
24th of 35
27 · median 35
Started
2026
with 3 others
Phase 2
22 of 69
4 open now
Primary completion
2029-06
later than 16 of 17 live
Registered
69th of 69
by date

Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 24th largest by planned enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 16 of the 17 other live ones, and was the 69th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatment.

03

Conditions studied

  • Colorectal Cancer
  • Adenocarcinoma of the Colon
  • Adenocarcinoma of the Rectum

Keywords

  • Colorectal Cancer
  • Adenocarcinoma of the Colon
  • Adenocarcinoma of the Rectum
  • T-DXd
  • 25-120
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed adenocarcinoma of the colon or rectum that is and/or unresectable.
  • Unless otherwise , participants must have received regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, and if the tumor is MSI-H/MMRd, a PD-(L)1 directed antibody. There is no maximum number of .
  • Prior anti- therapies other than T-DXd are allowed, with a of at least 4 weeks.
  • Prior anti-EGFR therapies, including cetuximab, are allowed, with a washout period of at least 4 weeks.
  • Have progression of unresectable or metastatic CRC after last systemic therapy (as confirmed by Investigator) or be intolerant of last systemic therapy.
  • Participants with KRAS/NRAS or BRAF-mutant colorectal tumors are eligible.
  • Willing and able to undergo baseline tumor , preferably of a lesion that has progressed since the last treatment, if feasible.
  • Have confirmed HER2-low mCRC, defined in this study by having tumor tissue tested at a CLIA-certified laboratory as HER2 IHC 1+ or 2+, as determined by Ventana's PATHWAY anti-HER2 (clone 4B5), an FDA-approved assay following the package insert's interpretational manual for gastric cancer, regardless of amplification by FISH. Archival tissue may be used for determination of HER2 status as long as tissue was obtained after last dose of most recent HER2-targeted therapy, if applicable.
  • Have radiographically according to v1.1, with at least one site of disease that is measurable and that has not been previously irradiated. If the participant has had previous radiation to the target lesion(s), there must be evidence of progression since radiation.
  • Age ≥18 years on the day of signing .
  • Have an performance status (ECOG PS) of 0 or 1.
  • Have parameters demonstrating adequate organ function, as defined below, obtained ≤14 days prior to the first study treatment, unless otherwise noted:

System / Laboratory value

Hematologic:

(ANC) / ≥1500/mm3 (G-CSF administration is not allowed within 14 days prior to screening assessment of bone marrow function, or at any time after this day and prior to initiation of treatment with study drug) / ≥9.0 g/dL (Red blood cell transfusion is not allowed within 14 days prior to screening assessment of bone marrow function, or at any time after this day and prior to initiation of treatment with study drug) count / ≥100,000/mm3 (Platelet transfusion is not allowed within 14 days prior to screening assessment of bone marrow function, or at any time after this day and prior to initiation of treatment with study drug)

Renal:

Serum creatinine or (as calculated using the Cockcroft-Gault equation) / ≤1.5 x or ≥50 mL/min

Hepatic:

(ALT), Aspartate aminotransferase (AST) / ≤2.5 x ULN if no liver metastases or ≤5x ULN if liver metastases are present Total / ≤1.5 x ULN if no liver metastases or \<3x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline Serum albumin / ≥2.5 g/dL

Coagulation (LVEF) as assessed by echocardiogram documented ≤28 days prior to study treatment / ≥50%

  • Have adequate treatment washout before enrollment (study treatment) as defined below:

Treatment / Washout Period

Major surgery / ≥4 weeks Radiation therapy / ≥4 weeks (if palliative stereotactic radiation therapy without abdominal involvement, ≥2 weeks) Chemotherapy (including antibody drug therapy, retinoid therapy) / ≥3 weeks for chemotherapeutics, ≥4 weeks for antibody drug therapy (e.g. bevacizumab, ramucirumab, cetuximab, trastuzumab) Immunotherapy / ≥4 weeks Cytochrome P450 (CYP)3A4 strong inhibitor, OATP inhibitor / ≥3 elimination half-lives of the inhibitor

  • Evidence of status or negative serum pregnancy test for females of (Section 6.3) who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit.
  • Male and female participants of reproductive/childbearing potential (Section 6.3) must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used. Methods considered as highly effective methods of contraception include:

    1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal.
    2. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable.
    3. Intrauterine device.
    4. Intrauterine hormone-releasing system.
    5. Bilateral tubal occlusion.
    6. Vasectomized partner.
    7. Complete and true sexual abstinence defined as abstinence when it is in line with the preferred lifestyle of the participant. Participants in this study should refrain from heterosexual intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence of the duration of exposure to study drug, and withdrawal are not acceptable methods of contraception.
    8. Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or post-menopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone >40 mIU/mL and estradiol \<40 pg/mL [\<147 pmol/L] is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of childbearing potential if they wish to continue HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between cessation of therapy and the blood draw. This interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without the use of contraceptive method.
    9. Male participants must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 4 months after the last dose of study drug to prevent pregnancy in a partner.
  • Male participants must not freeze or donate sperm starting at Screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study.
  • Female participants must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
  • Participants who are blood donors should not donate blood during the study and for 4 months following the last dose of study drug.
  • Patient or legally authorized representative (LAR) willing and able to sign informed consent document that has been approved by an IRB prior to initiation of any study-related tests or procedures that are not part of standard of care for the participant's disease.
  • Willing and able to comply with protocol visits and procedures.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
  • Previous enrollment in the present study.
  • Currently participating in another interventional clinical trial.
  • cardiopulmonary disease, such as:

    1. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( v5.0 ≥ Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.
    2. Congenital long syndrome.
    3. Corrected QT interval (QTcF) prolongation to >470 msec (females) or >450 msec (males) based on average of the screening triplicate 12-lead .
    4. History of QT prolongation associated with other medications that required discontinuation of that medication.
    5. History of symptomatic congestive heart failure (CHF) ( Class II to IV), left ventricular systolic dysfunction, or decrease in .
    6. History of myocardial infarction, unstable angina, vascular stenting, angioplasty, or other cardiac surgery within 6 months prior to first dose of study treatment.
    7. Uncontrolled or poorly controlled hypertension (>180 mmHg systolic or >130 mmHg diastolic) despite medical treatment.
    8. History of non-infectious ILD/pneumonitis that required , current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
    9. Severe dyspnea at rest (CTCAE v5.0 ≥ Grade 3) due to complications of advanced or hypoxia requiring supplemental oxygen therapy.
    10. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe [COPD], restrictive lung disease pleural effusion, etc.).
    11. Any , connective tissue, or inflammatory disorders (including Rheumatoid arthritis, Sjogren's, and sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for participants who are included in the study.
    12. Prior pneumonectomy (complete).
  • Any concomitant medications that are known to be associated with Torsades de Pointes or potent inducers of cytochrome P450 3A4 ().
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  • A pleural effusion, ascites, or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).
  • History of severe reactions to either the drug substances or inactive ingredients in the drug product(s).
  • History of severe hypersensitivity reactions to other monoclonal antibodies.
  • History of tick bite(s).
  • History of allergy to red meat.
  • Any toxicity related to prior anticancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:

    1. Alopecia and neuropathy, which must have resolved to ≤ Grade 2.
    2. CHF, which must have been ≤ Grade1 in severity at the time of occurrence and must have
  • Clinically significant corneal disease in the opinion of the Investigator.
  • Spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of definitive treatment (4 weeks if surgery) and study enrollment.
  • History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (e.g. 5-year OS ≥90%), such as adequately treated carcinoma in-situ of the cervix, adequately resected non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in-situ of the breast, or stage I uterine cancer). Cases should be reviewed by the study Principal Investigator.
  • Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.
  • Anticipated need for major surgical procedure during the course of the study.
  • Positive surface antigen or core antibody at screening.
  • Known to have active infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Participants who have been treated for hepatitis C infection are eligible if they have documented sustained virologic response of 12 weeks.
  • Known to be positive for (HIV). Participants should be tested for HIV prior to enrollment if required by local regulations or IRB/Ethics Committee (EC).
  • Prior treatment with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor.
  • Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated ) within 30 days prior to the first dose of T-DXd. Note: Participants, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of Product.
  • Pregnant (confirmed with positive pregnancy test), breastfeeding, or planning a pregnancy.
  • Social, familial, or geographical factors that would interfere with study participation or follow-up

Definitions

A person of is:

  • Anyone born female who has experienced menarche and who has not undergone surgical sterilization (e.g. hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or has not completed menopause. Menopause is defined clinically as 12 months of amenorrhea in a person born female over age 45 in the absence of other biological, physiological, or pharmacological causes.
  • Anyone born male who has testes and who has not undergone surgical sterilization (e.g. vasectomy followed by a clinical test proving that the procedure was effective).
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Safety Lead-In

    This study will begin with a Safety Lead-In of 6-18 participants to assess safety/tolerability of this novel combination and to determine the RP2D.

    Drug: Fam-Trastuzumab Deruxtecan-Nxki

  • Experimental
    Expansion Cohort

    If at least 1 out of 13 participants in the first stage has a complete or partial response (CR/PR), an additional 14 participants will be enrolled.

    Drug: Fam-Trastuzumab Deruxtecan-Nxki

Interventions

  • DrugTrastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The investigational study drug, fam-trastuzumab deruxtecan-nxki (ENHERTU® ), consists of an antibody component, MAAL-9001, covalently conjugated via a maleimide tetrapeptide linker, to a drug component, MAAA-1181a.

    Also known as: T-DXd

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    To determine the objective response rate (ORR), as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, of T-DXd + cetuximab in participants with HER2-low mCRC that has progressed on standard therapies.

    Time frame: Up to 1 year

07

Study locations

7 sites
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)
    Commack, New York 11725, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    • Rona Yaeger, MD · Contact646-888-5109
  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    • Rona Yaeger, MD · Contact646-888-5109
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2029, 32 months later.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 32 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 9, 2026
StartEst.
Oct 2026was Aug 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Oct 2026
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Aug 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07691489
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Rona Yaeger, MD
Contact
yaegerr@mskcc.org
646-888-5109
Andrea Cercek, MD
Contact
cerceka@mskcc.org
646-888-4189
Rona Yaeger, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion